朗齊生醫*（以下簡稱＂朗齊＂，股票代號：6876）今日獲駐瑞士台北文化經濟代表團王思為大使於瑞士代表處接見，雙方針對台灣生技產業在歐洲市場的戰略佈局、抗腫瘤藥物開發與代謝性疾病治療等前瞻議題，進行深入交流。王大使表示，瑞士擁有全球頂尖的製藥大廠與高度成熟的生技聚落，台灣在生醫研發、智慧醫療與醫療衛生發展成果顯著，雙方合作將可共同創造生醫及醫療外交新亮點。 瑞士是全球頂尖的生物技術與生命科學強國，在全球創新指數（GlobalInnovation Index，GII）的排名連續14年蟬聯第一，顯見其在生物技術研究及創新領域的全球影響力。朗齊在此次會晤中，詳盡展示了癌症治療（LXP108）與代謝疾病（LXP103）雙主軸Pipeline的最新進展，其中優異的實驗數據與臨床表現，成為台瑞生醫對談的焦點。 LXP108為一款具備高度潛力的廣譜抗癌新藥，在低濃度下即可抑制至少15種致癌蛋白激酶，對於肺癌、口腔癌、胃癌等致死率極高的癌症展現顯著藥效，曾榮獲王民寧獎與未來科技突破獎。目前臨床一期劑量遞增試驗進展順利，已完成第四劑量組（0.72 mg/kg）評估，安全性與耐受性極佳。朗齊預計於2027年完成一期試驗後，積極展開跨國授權與商業合作。 針對全球千億美元規模的減重市場，朗齊自主開發的LXP103展現了顛覆性的數據。實驗證實 LXP103具備「不靠少吃、純靠代謝調節」的特性，大鼠模型在不改變飲食習慣下，體寬縮減達23％，且體重增幅抑制率高達91.4％，成功解決了現行減重藥物「停藥即反彈」的痛點。更關鍵的是，LXP103具有極乾淨的毒理紀錄，不影響食欲且無常見副作用。該藥物預計於今年底叩關美國FDA申請一期人體臨床。 此外，朗齊亦簡報了針對三陰性乳癌研發的LXP105，預計於2026年底至2027年初向FDA申請二期臨床，持續填補全球癌症治療的缺口。 王思為大使在會談中高度肯定朗齊生醫的研發成果，並表示朗齊生醫的表現正是台灣生技產業蓬勃發展的縮影。 王大使強調：「朗齊生醫展現了台灣生技產業『小而美、反應快、技術精』的優勢。無論是LXP108在癌症精準醫療的深度佈局，或是LXP103針對代謝管理趨勢的創新突破，都顯示台灣企業不僅能緊跟全球生技醫藥產業趨勢，更能透過差異化開發策略，在國際藥物開發舞台上佔據重要地位。」 王大使亦指出，瑞士作為全球製藥龍頭與生技聚落的重鎮，化學及製藥產業占瑞士總出口約一半，具備全球視野和開放性的跨國合作，是台灣生醫公司走向國際的最佳跳板。駐處未來將持續發揮橋樑功能，協助具備堅實數據支持的台灣企業與歐洲生醫產業鏈對接，深化雙邊科技合作，呼應外交部「榮邦計畫」，打造台灣與國際夥伴生醫及醫療產業的共同繁榮。
## Longi Biotech Meets with Taiwanese Ambassador to Switzerland to Advance European Market Expansion and Dual-Core Pipeline
**Switzerland** — **Longi Biotech** (hereinafter referred to as “Longi”, Stock Code: 6876) was received today by Ambassador Wang Si-wei of the Taipei Cultural and Economic Delegation in Switzerland at the representative office. The two parties engaged in an in-depth exchange on forward-looking topics, including the strategic layout of Taiwan’s biotechnology industry in the European market, anti-tumor drug development, and treatments for metabolic diseases.
Ambassador Wang stated that Switzerland possesses world-leading pharmaceutical giants and a highly mature biotech cluster, while Taiwan has achieved significant milestones in biomedical R&D, smart healthcare, and medical and health development. Cooperation between the two sides will jointly create new highlights in biomedical and medical diplomacy.
Switzerland is a top global powerhouse in biotechnology and life sciences, ranking first in the Global Innovation Index (GII) for 14 consecutive years, which underscores its global influence in biotech research and innovation. During the meeting, Longi presented a detailed overview of the latest progress in its dual-core pipeline: **cancer therapy (LXP108)** and **metabolic diseases (LXP103)**. The outstanding experimental data and clinical performance became the central focus of this Taiwan-Switzerland biomedical dialogue.
—
### LXP108: A High-Potential Broad-Spectrum Anti-Cancer Novel Drug
LXP108 is a highly promising broad-spectrum anti-cancer novel drug capable of inhibiting at least 15 oncogenic protein kinases at low concentrations. It has demonstrated significant efficacy against high-mortality cancers such as lung, oral, and gastric cancers, and was previously honored with the *Wang Min-Ning Award* and the *Future Tech Breakthrough Award*.
* **Clinical Progress:** Currently, the Phase I clinical dose-escalation trial is progressing smoothly, having completed the evaluation of the fourth cohort (0.72 mg/kg) with excellent safety and tolerability.
* **Future Outlook:** Longi expects to complete the Phase I trial in 2027, after which it will actively pursue cross-border licensing and commercial collaborations.
### LXP103: Disrupting the Weight-Loss Market with Metabolic Regulation
Targeting the global hundred-billion-dollar weight-loss market, Longi’s self-developed LXP103 has demonstrated disruptive data. Experiments have confirmed that LXP103 features a **”no diet restrictions, pure metabolic regulation”** mechanism.
* **Efficacy Data:** In rat models, without changing dietary habits, body width was reduced by up to 23%, and the inhibition rate of weight gain reached as high as 91.4%. This successfully addresses the major pain point of current weight-loss drugs: the “rebound effect” upon discontinuation.
* **Safety Profile:** Crucially, LXP103 boasts an exceptionally clean toxicological profile, does not affect appetite, and exhibits no common side effects.
* **Timeline:** The drug is expected to submit an Investigational New Drug (IND) application to the US FDA for Phase I human clinical trials by the end of this year.
### LXP105: Addressing Triple-Negative Breast Cancer (TNBC)
Additionally, Longi briefed the Ambassador on LXP105, which is being developed for triple-negative breast cancer. Longi plans to apply for Phase II clinical trials with the US FDA between late 2026 and early 2027, continuing to fill critical gaps in global cancer treatment.
—
### Strong Diplomatic Support for Taiwan’s Biotech Innovations
Ambassador Wang Si-wei highly commended Longi’s R&D achievements during the meeting, noting that Longi’s performance is a miniature of the thriving development of Taiwan’s biotech industry.
> “Longi Biotech showcases the advantages of Taiwan’s biotech industry—being ‘small yet beautiful, quick to respond, and technologically sophisticated,'” Ambassador Wang emphasized. “Whether it is the profound layout of LXP108 in precision oncology or the innovative breakthrough of LXP103 targeting metabolic management trends, it demonstrates that Taiwanese companies can not only keep pace with global biomedical trends but also occupy a vital position on the international drug development stage through differentiated development strategies.”
Ambassador Wang also pointed out that Switzerland, as a global pharmaceutical leader and a key biotech hub, sees its chemical and pharmaceutical industries account for about half of its total exports. Cross-border cooperation with a global vision and openness serves as the best springboard for Taiwanese biomedical companies to go international.
In the future, the representative office will continue to serve as a bridge to help data-backed Taiwanese enterprises connect with the European biomedical supply chain. This will deepen bilateral tech cooperation and echo the Ministry of Foreign Affairs’ **”Prosperity Plan”** (榮邦計畫), forging shared prosperity in the biomedical and healthcare industries between Taiwan and its international partners.
